In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vaccine Therapies Show Promise In Fight Against Cervical Cancer

Executive Summary

The eradication of cervical cancer is on the horizon, stirring further competition between biopharma companies developing novel cancer vaccines.

You may also be interested in...



Serum Scores A Double - HPV Vaccine In India, Novavax Vaccine In US

Serum Institute will supply initial doses of NVX-CoV2373 in the US, but late approvals have meant Novavax's vaccine is facing weak demand and surplus stocks in other parts of the world. Meanwhile, Serum has also secured a nod in India for the first indigenously-developed HPV vaccine, also the fifth globally.

Improving Clinical Trials In Psychiatric Health Care

Kiri Granger, Monument Therapeutics’ chief scientific officer and executive director, and one of In Vivo’s 2022 Rising Leaders, hopes to take the company to the next level by rejecting the conventional one-size-fits-all approach to psychiatric clinical trials.

Rising Leaders Class Of 2020: Where Are They Now?

In 2020, In Vivo launched its annual Rising Leaders list to spotlight talent across the life sciences industry. The editorial team selected 30 individuals from across the biopharma, medtech, academic and healthtech sectors. Here we revisit the class of 2020 and see where they are now.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV125011

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel